Table 2. Time to metastasis using multivariate Cox-regression.
| Variable | Unadjusted (UVA) | Adjusted (MVA) | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | |
| Gleason Score | ||||||
| 9 | 1 | – | – | 1 | – | – |
| 10 | 3.373 | 0.388 to 29.338 | 0.27 | 6.189 | 0.366 to 104.760 | 0.2 |
| Stage | ||||||
| IIIC | 1 | – | – | 1 | – | – |
| IVA | 4.181 | 0.339 to 51.518 | 0.26 | 5.411 | 0.295 to 99.348 | 0.25 |
| IVB | 6.856 | 1.134 to 41.442 | 0.03 | 9.702 | 0.840 to 112.038 | 0.06 |
| ADT length | ||||||
| ≤18 months | 1 | – | – | 1 | – | – |
| >18 months | 2.225 | 0.445 to 11.116 | 0.33 | 2.664 | 0.280 to 25.301 | 0.39 |
| Responder group | ||||||
| Early | 1 | – | – | 1 | – | – |
| Late | 1.651 | 0.324 to 8.408 | 0.55 | 0.391 | 0.048 to 3.195 | 0.38 |
| Ricketts risk group | ||||||
| High | 1 | – | – | – | – | – |
| Low | 4.04 | 0.783 to 20.844 | 0.09 | 9.256 | 1.061 to 80.719 | 0.04 |
P values <0.05 are bold for significance.
ADT, androgen deprivation therapy; MVA, multivariable analysis; UVA, univariable analysis.